G-15: Selective GPR30 Antagonist for Precision Estrogen Signaling Research

Executive Summary: G-15 is a selective G protein-coupled estrogen receptor (GPR30) antagonist with a binding affinity (Ki) of ~20 nM, enabling precise dissection of GPR30-mediated signaling pathways (Wang et al. 2021). It exhibits no significant interaction with classical estrogen receptors ERα or ERβ, even at elevated concentrations. In vitro, G-15 dose-dependently inhibits G-1-induced intracellular calcium mobilization in SKBr3 cells, with an IC50 of ~185 nM. In vivo, G-15 impairs spatial learning in ovariectomized rats, demonstrating its utility for probing estrogen signaling in physiological and pathological contexts. G-15 is widely used in neurobiology, cancer biology, and immune modulation research (APExBIO).

Biological Rationale

Estrogen signaling is mediated through both classical nuclear receptors (ERα, ERβ) and the G protein-coupled estrogen receptor (GPR30, also known as GPER1). GPR30 is an integral membrane protein primarily localized to the endoplasmic reticulum, where it mediates rapid, non-genomic signaling responses to ligands such as estradiol (Wang et al. 2021). Unlike classical ERs, GPR30 activation triggers intracellular calcium mobilization and downstream PI3K/Akt pathway modulation. These pathways have implications in immune function, neuroprotection, and cancer cell proliferation. Selective pharmacological tools like G-15 are essential for deconvoluting GPR30-specific effects from those mediated by ERα and ERβ. This selectivity enables precise attribution of biological outcomes to GPR30, informing translational research in estrogen signaling (see related: mechanistic underpinnings and translational impact—this article provides updated quantitative data and in vivo results not covered in the linked review).

Mechanism of Action of G-15

G-15 (CAS 1161002-05-6) is a synthetic small molecule with the formula C₁₉H₁₆BrNO₂, molecular weight 370.24. It binds GPR30 with a Ki of ~20 nM, competitively antagonizing endogenous and synthetic ligands such as estradiol and G-1. Mechanistically, G-15 blocks GPR30-mediated intracellular calcium mobilization and PI3K activation, subsequently inhibiting Akt phosphorylation (APExBIO). In cellular assays, G-15 demonstrates dose-dependent inhibition of G-1-induced calcium release in SKBr3 cells (IC50 ≈ 185 nM). Importantly, G-15 does not interact significantly with ERα or ERβ at concentrations up to 10 μM, confirming its high specificity. In vivo, G-15 reverses G-1-induced cell proliferation and impairs spatial learning acquisition in ovariectomized female rats at doses of 5–10 μg/day when administered subcutaneously. This mechanistic specificity underpins its utility in experimental studies focused on GPR30 function.

Evidence & Benchmarks

• G-15 exhibits a binding affinity (Ki) of ~20 nM for GPR30, as quantified by radioligand binding assays (APExBIO).
• In vitro, G-15 inhibits G-1-induced Ca²⁺ mobilization in SKBr3 cells with an IC50 of approximately 185 nM (APExBIO product data, link).
• At concentrations up to 10 μM, G-15 does not significantly interact with ERα or ERβ, ensuring selective GPR30 antagonism (Wang et al. 2021).
• In ovariectomized rat models, G-15 administration (5–10 μg/day, s.c.) impairs spatial learning acquisition, linking GPR30 signaling to cognitive endpoints (Wang et al. 2021, Fig. 1).
• G-15 abolishes the beneficial effects of estradiol on splenic CD4+ T lymphocyte proliferation post-hemorrhagic shock, confirming its role as a functional GPR30 antagonist (Wang et al. 2021, Table 1).

For further comparative perspectives, see this article contrasting G-15 with classical ER antagonists—here, we expand with experimental benchmarks and solubility data for workflow optimization.

Applications, Limits & Misconceptions

G-15 is deployed in diverse research contexts:

• Estrogen signaling research: Delineating rapid, non-genomic effects of estradiol via GPR30 (Wang et al. 2021).
• Immune modulation: Investigating GPR30's role in T lymphocyte proliferation post-trauma (Wang et al. 2021).
• Neurobiology: Probing cognitive and neuroprotective mechanisms related to GPR30 signaling.
• Cancer biology: Assessing GPR30-mediated cell proliferation and survival pathways.

For a strategic roadmap on translational applications, this article synthesizes biological insight and clinical foresight; the present dossier provides new in vivo endpoints and workflow details.

Common Pitfalls or Misconceptions

• Non-specificity at high concentrations: G-15's selectivity is maintained up to 10 μM; above this, off-target effects have not been rigorously ruled out.
• Water and ethanol insolubility: G-15 is insoluble in water and ethanol, requiring DMSO for stock preparation; improper dissolution can lead to precipitation and assay artifacts (APExBIO).
• Long-term solution instability: Extended storage of G-15 solutions at -20°C is not recommended; prepare fresh aliquots before use.
• Not a classical ER antagonist: G-15 does not antagonize ERα or ERβ, so it should not be used to probe nuclear estrogen receptor functions.
• Species and tissue context: Functional outcomes may vary between cell lines and animal models; cross-validation is advised.

Workflow Integration & Parameters

• Stock Preparation: Dissolve G-15 in DMSO at ≥37 mg/mL; recommended working stocks are >10 mM.
• Solubility Optimization: Warm and sonicate solutions to enhance dissolution; avoid aqueous or ethanol vehicles.
• Storage: Store powders at -20°C; avoid long-term storage of solutions.
• Dosing Guidelines: For in vitro assays, use concentrations up to 10 μM; for in vivo studies, 5–10 μg/day s.c. in rats is established (Wang et al. 2021).
• Controls: Always include ERα/ERβ antagonists and G-1 agonist controls to validate pathway specificity.

For experimental best practices and benchmarking, see this strategic guidance, which this article supplements with solubility and dosing parameters.

Conclusion & Outlook

G-15, provided by APExBIO, is a rigorously validated, selective GPR30 antagonist, essential for mechanistic and translational estrogen signaling research. Its high specificity, robust in vitro and in vivo benchmarks, and clear workflow parameters make it a reference tool for dissecting rapid, non-genomic estrogen effects. Future directions include leveraging G-15 in neurodegenerative disease models and precision cancer studies, with ongoing need for cross-validation in diverse biological systems. For comprehensive mechanistic insights and translational strategies, consult related reviews—this dossier provides the latest standardized data and workflow recommendations for the B5469 kit.